Related Experiment Video
Updated: Aug 6, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Real-World Effectiveness and Safety of a Tubeless Automated Insulin Delivery System With an Adaptive Control
Angela Zanfardino1, Dario Iafusco1, Giorgia Ippolito1
1Regional Centre for Pediatric Diabetes, Department of Pediatrics, University of the Study of Campania, Naples, Italy.
Aim:
Automated insulin delivery (AID) systems improve glycaemic outcomes in Type 1 diabetes; however, paediatric real-world data on newly introduced tubeless AID systems remain limited. We aimed to provide the first clinical evaluation of the A8 TouchCare Nano AID system with the APGO algorithm in children and adolescents with Type 1 diabetes.
Materials And Methods:
In this prospective observational study, children and adolescents initiating TouchCare Nano AID therapy were followed for 6 months. Continuous glucose monitoring metrics were assessed at baseline and 1, 3 and 6 months. The primary outcome was change in time in range (TIR, 70-180 mg/dL). Secondary outcomes included time in tight range (TiTR, 70-140 mg/dL), time above and below range, glucose variability, insulin dose, achievement of ISPAD glycaemic targets and safety. HbA1c was measured at baseline, 3 and 6 months.
Results:
Seventy-six participants (mean age 13.3 ± 3.2 years) completed follow-up. Mean TIR increased from 59.0% ± 15.6% at baseline to 74.2% ± 8.9% at 1 month and remained significantly higher at 3 and 6 months (all p < 0.05). TiTR significantly improved, whilst time above range decreased and time below range remained stable. More than half of participants achieved the ISPAD target of TIR > 70% at 6 months. Mean sensor glucose and glucose variability declined, and HbA1c decreased from 7.4% ± 0.8% to 6.9% ± 0.7% at 3 and 6 months (all p < 0.05). No episodes of severe hypoglycaemia or diabetic ketoacidosis were observed.
Conclusions:
In routine paediatric care, use of this tubeless AID system was associated with rapid and sustained improvements in glycaemic control without increased hypoglycaemia.
Trial Registration:
Clinicaltrials.gov: NCT07425912.
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes I: Introduction
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into rapid-acting...
Diabetes Mellitus: Type 2 and Gestational